1. OP01 In-depth characterisation of host genetics and gut microbiome unravels novel host–microbiome interactions in inflammatory bowel disease. (25th January 2019) Authors: Hu, S; Vich Vila, A; Gacesa, R; Collij, V; Xavier, R; Stevens, C; Daly, M; Wijmenga, C; van Dullemen, H; Dijkstra, G; Visschedijk, M; Festen, E; Fu, J; Kurilshikov, A; Zhernakova, A; Weersma, R Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP028 Single cell RNA sequencing of t-cells in Crohn's disease identifies tissue specific drug targets. (16th January 2018) Authors: Festen, E; Weersma, R; Uniken Venema, W T; Voskuil, M D; Graham, D Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S019 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P033 Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment. (21st January 2022) Authors: Karmi, N; Sun, S; de Jong, S; Bangma, A; Teunis, J; Paraskevopoulou, M; Juarez, J; Bleck, B; Farahmand, S; Weersma, R; Bigaeva, E; Festen, E Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP04 Single cell RNA sequencing identifies distinct intestinal inflammation patterns between primary sclerosing cholangitis-associated colitis and Ulcerative Colitis. (27th May 2021) Authors: Uniken Venema, W; Bangma, A; Van der Wijst, M; Kats-Ugurlu, G; Bjork, J; Vich Vila, A; Weersma, R; Festen, E Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P812 Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution in patients with inflammatory bowel disease. (30th January 2023) Authors: Van Der Waaij, A; Gabriëls, R; Linssen, M; Volkmer, P; Robinson, D; Hermoso, M; Karrenbeld, A; Festen, E; Dijkstra, G; Kats-Urgulu, G; Nagengast, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i944 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗